Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombectomy | 18 | 2026 | 242 | 2.480 |
Why?
|
| Stents | 19 | 2026 | 493 | 1.970 |
Why?
|
| Intracranial Aneurysm | 8 | 2026 | 374 | 1.850 |
Why?
|
| Embolization, Therapeutic | 6 | 2024 | 328 | 1.820 |
Why?
|
| Endovascular Procedures | 11 | 2025 | 607 | 1.700 |
Why?
|
| Cerebral Angiography | 8 | 2024 | 295 | 1.620 |
Why?
|
| Stroke | 13 | 2024 | 1196 | 1.460 |
Why?
|
| Aneurysm, Ruptured | 4 | 2026 | 79 | 1.240 |
Why?
|
| Carotid Stenosis | 3 | 2022 | 98 | 1.240 |
Why?
|
| Radial Artery | 4 | 2022 | 54 | 1.220 |
Why?
|
| Catheters | 6 | 2026 | 78 | 1.040 |
Why?
|
| Subarachnoid Hemorrhage | 3 | 2023 | 109 | 1.030 |
Why?
|
| Transverse Sinuses | 2 | 2022 | 6 | 0.920 |
Why?
|
| Carotid Artery, Internal | 7 | 2023 | 68 | 0.890 |
Why?
|
| Brain Ischemia | 8 | 2022 | 421 | 0.860 |
Why?
|
| Treatment Outcome | 27 | 2026 | 5697 | 0.800 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2023 | 24 | 0.780 |
Why?
|
| Mucopolysaccharidosis II | 1 | 2022 | 10 | 0.770 |
Why?
|
| Femoral Artery | 2 | 2022 | 99 | 0.750 |
Why?
|
| Central Nervous System Vascular Malformations | 5 | 2022 | 75 | 0.750 |
Why?
|
| Lithotripsy | 1 | 2022 | 10 | 0.740 |
Why?
|
| Vascular Calcification | 1 | 2022 | 26 | 0.720 |
Why?
|
| Retrospective Studies | 28 | 2026 | 6742 | 0.660 |
Why?
|
| Trastuzumab | 4 | 2023 | 20 | 0.580 |
Why?
|
| Humans | 57 | 2026 | 64279 | 0.550 |
Why?
|
| Immunoconjugates | 3 | 2023 | 93 | 0.510 |
Why?
|
| Cranial Sinuses | 3 | 2022 | 12 | 0.480 |
Why?
|
| Aged | 26 | 2026 | 14664 | 0.450 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2026 | 233 | 0.440 |
Why?
|
| Thrombosis | 3 | 2022 | 198 | 0.430 |
Why?
|
| Middle Aged | 28 | 2026 | 17923 | 0.410 |
Why?
|
| Aged, 80 and over | 14 | 2026 | 5528 | 0.410 |
Why?
|
| Female | 34 | 2026 | 33382 | 0.390 |
Why?
|
| Camptothecin | 3 | 2023 | 29 | 0.370 |
Why?
|
| Male | 31 | 2026 | 30323 | 0.340 |
Why?
|
| Infarction, Middle Cerebral Artery | 2 | 2025 | 87 | 0.340 |
Why?
|
| Cavernous Sinus | 1 | 2010 | 8 | 0.320 |
Why?
|
| Veins | 1 | 2010 | 64 | 0.310 |
Why?
|
| Aneurysm, False | 2 | 2022 | 50 | 0.310 |
Why?
|
| Anterior Cerebral Artery | 2 | 2025 | 9 | 0.290 |
Why?
|
| Pseudotumor Cerebri | 2 | 2018 | 11 | 0.280 |
Why?
|
| Carotid Artery Diseases | 2 | 2018 | 61 | 0.270 |
Why?
|
| Hematoma | 2 | 2024 | 80 | 0.250 |
Why?
|
| Constriction, Pathologic | 3 | 2022 | 132 | 0.250 |
Why?
|
| Adenosine Monophosphate | 1 | 2026 | 30 | 0.240 |
Why?
|
| Angiography | 4 | 2020 | 151 | 0.240 |
Why?
|
| Incidence | 4 | 2022 | 1385 | 0.240 |
Why?
|
| Cerebral Revascularization | 2 | 2017 | 30 | 0.230 |
Why?
|
| Reperfusion | 1 | 2025 | 37 | 0.230 |
Why?
|
| Social Class | 1 | 2026 | 137 | 0.230 |
Why?
|
| Adult | 18 | 2026 | 17133 | 0.230 |
Why?
|
| Endarterectomy, Carotid | 2 | 2017 | 79 | 0.220 |
Why?
|
| Platelet Function Tests | 1 | 2024 | 11 | 0.210 |
Why?
|
| Moyamoya Disease | 1 | 2024 | 12 | 0.210 |
Why?
|
| Posterior Cerebral Artery | 1 | 2023 | 13 | 0.210 |
Why?
|
| Cerebral Veins | 1 | 2023 | 36 | 0.200 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2022 | 5 | 0.200 |
Why?
|
| Registries | 2 | 2025 | 885 | 0.190 |
Why?
|
| Tinnitus | 1 | 2022 | 19 | 0.190 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2023 | 48 | 0.190 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2023 | 167 | 0.190 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 83 | 0.190 |
Why?
|
| Cerebral Hemorrhage | 2 | 2022 | 100 | 0.190 |
Why?
|
| Maytansine | 1 | 2022 | 5 | 0.190 |
Why?
|
| Intracranial Hemorrhages | 1 | 2022 | 68 | 0.190 |
Why?
|
| Vasospasm, Intracranial | 1 | 2022 | 30 | 0.190 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 1213 | 0.190 |
Why?
|
| Carotid Artery, Internal, Dissection | 1 | 2022 | 19 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 50 | 0.180 |
Why?
|
| Carotid Arteries | 1 | 2022 | 61 | 0.180 |
Why?
|
| Phlebography | 2 | 2018 | 44 | 0.180 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2022 | 29 | 0.180 |
Why?
|
| Nerve Block | 1 | 2022 | 57 | 0.180 |
Why?
|
| Radiography, Interventional | 2 | 2022 | 81 | 0.170 |
Why?
|
| One-Lung Ventilation | 1 | 2020 | 5 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 457 | 0.160 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2023 | 222 | 0.160 |
Why?
|
| Prospective Studies | 7 | 2025 | 3318 | 0.160 |
Why?
|
| Brain | 3 | 2023 | 1581 | 0.150 |
Why?
|
| Neurosurgical Procedures | 1 | 2020 | 101 | 0.150 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2020 | 140 | 0.140 |
Why?
|
| Intracranial Hypotension | 1 | 2018 | 10 | 0.140 |
Why?
|
| Ocular Motility Disorders | 1 | 2017 | 3 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 81 | 0.130 |
Why?
|
| Workload | 1 | 2018 | 127 | 0.130 |
Why?
|
| Pneumonia | 1 | 2020 | 291 | 0.130 |
Why?
|
| Arteries | 1 | 2017 | 80 | 0.130 |
Why?
|
| Operative Time | 1 | 2017 | 91 | 0.130 |
Why?
|
| Blood Pressure | 1 | 2019 | 517 | 0.130 |
Why?
|
| Feasibility Studies | 3 | 2025 | 577 | 0.130 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2017 | 127 | 0.130 |
Why?
|
| Radiation Dosage | 1 | 2017 | 138 | 0.130 |
Why?
|
| Phantoms, Imaging | 1 | 2017 | 225 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 1669 | 0.120 |
Why?
|
| Patient Selection | 1 | 2018 | 487 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2018 | 428 | 0.110 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 267 | 0.110 |
Why?
|
| Contrast Media | 1 | 2016 | 429 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2026 | 2605 | 0.100 |
Why?
|
| Neurosurgery | 1 | 2013 | 30 | 0.100 |
Why?
|
| Computed Tomography Angiography | 3 | 2019 | 129 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 2482 | 0.100 |
Why?
|
| Heart-Assist Devices | 1 | 2015 | 149 | 0.100 |
Why?
|
| Ultrasonic Therapy | 1 | 2012 | 9 | 0.100 |
Why?
|
| Physicians | 1 | 2018 | 483 | 0.090 |
Why?
|
| Angioplasty | 1 | 2012 | 51 | 0.090 |
Why?
|
| Embolism, Paradoxical | 1 | 2012 | 14 | 0.090 |
Why?
|
| Caregivers | 1 | 2015 | 283 | 0.090 |
Why?
|
| Eating | 2 | 2022 | 139 | 0.090 |
Why?
|
| Drainage | 2 | 2023 | 155 | 0.090 |
Why?
|
| Dura Mater | 1 | 2010 | 33 | 0.080 |
Why?
|
| Catheterization | 1 | 2010 | 113 | 0.080 |
Why?
|
| Neoplasms | 1 | 2020 | 1392 | 0.080 |
Why?
|
| Intracranial Pressure | 2 | 2018 | 20 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 984 | 0.070 |
Why?
|
| Quality of Life | 1 | 2015 | 1257 | 0.070 |
Why?
|
| Cerebral Infarction | 2 | 2022 | 84 | 0.070 |
Why?
|
| Young Adult | 3 | 2026 | 4781 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2738 | 0.070 |
Why?
|
| Heart Failure | 1 | 2015 | 926 | 0.060 |
Why?
|
| Vascular Surgical Procedures | 2 | 2021 | 244 | 0.060 |
Why?
|
| United States | 3 | 2026 | 7923 | 0.060 |
Why?
|
| Suction | 1 | 2025 | 35 | 0.060 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2017 | 138 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2023 | 2218 | 0.060 |
Why?
|
| Postoperative Complications | 2 | 2024 | 1301 | 0.050 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2024 | 16 | 0.050 |
Why?
|
| Mechanical Thrombolysis | 1 | 2024 | 37 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2026 | 869 | 0.050 |
Why?
|
| Japan | 1 | 2023 | 60 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2024 | 73 | 0.050 |
Why?
|
| Sympathectomy | 1 | 2022 | 5 | 0.050 |
Why?
|
| Aspirin | 1 | 2024 | 172 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2023 | 124 | 0.050 |
Why?
|
| Subclavian Artery | 1 | 2022 | 26 | 0.050 |
Why?
|
| Cannula | 1 | 2022 | 24 | 0.050 |
Why?
|
| Dilatation | 1 | 2022 | 31 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2022 | 68 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2022 | 68 | 0.050 |
Why?
|
| Circle of Willis | 1 | 2021 | 7 | 0.040 |
Why?
|
| Adolescent | 2 | 2026 | 6305 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2023 | 288 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2023 | 482 | 0.040 |
Why?
|
| Carotid Artery, Common | 1 | 2020 | 29 | 0.040 |
Why?
|
| Everolimus | 1 | 2020 | 22 | 0.040 |
Why?
|
| Bronchi | 1 | 2020 | 84 | 0.040 |
Why?
|
| Trachea | 1 | 2020 | 85 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 38 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 103 | 0.040 |
Why?
|
| Arteriovenous Malformations | 1 | 2020 | 44 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 210 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 37 | 0.040 |
Why?
|
| Child | 2 | 2020 | 4583 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 1561 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 206 | 0.040 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 203 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 237 | 0.040 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2018 | 31 | 0.040 |
Why?
|
| Blister | 1 | 2018 | 16 | 0.030 |
Why?
|
| Models, Biological | 1 | 2023 | 1187 | 0.030 |
Why?
|
| Headache | 1 | 2018 | 58 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 2017 | 66 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 176 | 0.030 |
Why?
|
| Acute Disease | 1 | 2019 | 672 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 299 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 859 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 759 | 0.030 |
Why?
|
| Reoperation | 1 | 2017 | 292 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 856 | 0.030 |
Why?
|
| Hospitals | 1 | 2018 | 390 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 2019 | 0.030 |
Why?
|
| Hypertension | 1 | 2019 | 593 | 0.030 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2013 | 17 | 0.030 |
Why?
|
| Heart Ventricles | 1 | 2015 | 265 | 0.030 |
Why?
|
| India | 1 | 2013 | 158 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2013 | 206 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 3726 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 652 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 553 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 266 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 2621 | 0.010 |
Why?
|